Produits et services

Radiopharmaceutical preparations for use in oncology, in particular lutetium-containing radiopharmaceuticals for the treatment and diagnosis of tumours.

Produits et services

Chemical substances, chemical materials and chemical preparations for use in the manufacture of medical and/or radiopharmaceutical products; chemical raw materials, in particular actinium-225 radiochemical and/or bismuth-213, for the formulation of radiopharmaceutical products. Radiopharmaceutical diagnostic and/or therapeutic preparations for medical and/or pharmaceutical purposes, in particular radiopharmaceutical preparations for endoradionuclide therapy, brachytherapy, positron emission tomography (PET), single photon emission computed tomography (SPECT), target radionuclide therapy and peptide receptor radionuclide therapy (PRRT); radiopharmaceutical products, in particular actinium-containing and/or bismuth-containing radiopharmaceutical products in GMP [Good Manufacturing Practice] quality; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular actinium-225 and/or bismuth-213; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular actinium-225 and/or bismuth-213 for the treatment of tumour diseases; target radiopharmaceuticals containing a target molecule, in particular a peptide or an antibody, depending on the indication, and a medical radioactive isotope; radiopharmaceuticals containing actinium-225 and/or bismuth-213 and its complexes. Medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, in particular for the production of actinium-225 and/or bismuth-213 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of actinium-225 and/or bismuth-213 in GMP quality; radionuclide generator for radiopharmaceutical purpose. Scientific and technological services and research relating to the use of actinium-225 and/or bismuth-213 or other alpha emitters, in particular medical and pharmacological research services relating to the use of actinium-225 and/or bismuth-213 or other alpha emitters. Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and radionuclide therapy, peptide receptor radionuclide therapy (PRRT), personal nuclear medicine and precision oncology; medical services for theranostics in the field of precision oncology.

Produits et services

Radiopharmaceutical preparations for use in oncology, in particular lutetium-containing radiopharmaceuticals for the treatment and diagnosis of tumours.

Produits et services

(1) Radiopharmaceutical preparations for use in oncology, in particular lutetium-containing radiopharmaceuticals for the treatment and diagnosis of tumours.

Produits et services

Chemical substances, chemical materials and chemical preparations for use in the manufacture of medical products; chemical substances, chemical materials and chemical preparations for use in the manufacture of radiopharmaceutical products; chemical raw materials, in particular actinium-225 radiochemical, for the formulation of radiopharmaceutical products; chemical raw materials, in particular bismuth-213, for the formulation of radiopharmaceutical products Radiopharmaceutical diagnostic preparations for medical purposes; radiopharmaceutical diagnostic preparations for pharmaceutical purposes; radiopharmaceutical therapeutic preparations for medical purposes; radiopharmaceutical therapeutic preparations for pharmaceutical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy, positron emission tomography, single photon emission computed tomography, target radionuclide therapy and peptide receptor radionuclide therapy; radiopharmaceutical preparations, in particular actinium-containing radiopharmaceutical products in GMP quality; radiopharmaceutical preparations, in particular bismuth-containing radiopharmaceutical products in GMP quality; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular actinium-225; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular bismuth-213; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular actinium-225 for the treatment of tumour diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular bismuth-213 for the treatment of tumour diseases; target radiopharmaceuticals containing a target molecule, in particular peptide , depending on the indication, and a medical radioactive isotope; target radiopharmaceuticals containing a target molecule, in particular an antibody depending, on the indication, and a medical radioactive isotope; radiopharmaceuticals containing actinium-225 and its complexes; radiopharmaceuticals containing bismuth-213 and its complexes Medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, namely sample preparation devices automatically or manually operated in particular for the production of actinium-225 in GMP quality; medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, namely sample preparation devices automatically or manually operated in particular for the production of bismuth-213 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers, in particular devices containing fluidic processing components as valves, small vessels (5-500 ml) and purification columns for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of actinium-225 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular devices containing fluidic processing components as valves, small vessels (5-500 ml) and purification columns for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of bismuth-213 in GMP quality; radionuclide generator for radiopharmaceutical purpose Scientific and technological services and research relating to the use of actinium-225, in particular medical and pharmacological research services relating to the use of actinium-225; scientific and technological services and research relating to the use of bismuth-213, in particular medical and pharmacological research services relating to the use of bismuth-213; scientific and technological services and research relating to the use of other alpha emitters, in particular medical and pharmacological research services relating to the use of other alpha emitters Medical services, in particular medical services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies, namely intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and radionuclide therapy, peptide receptor radionuclide therapy, personal nuclear medicine and precision oncology; medical services for theranostics in the field of precision oncology

Produits et services

(1) Chemical substances, chemical materials and chemical preparations for use in the manufacture of medical and/or radiopharmaceutical products; chemical raw materials, in particular actinium-225 radiochemical and/or bismuth-213, for the formulation of radiopharmaceutical products. (2) Radiopharmaceutical diagnostic and/or therapeutic preparations for medical and/or pharmaceutical purposes, in particular radiopharmaceutical preparations for endoradionuclide therapy, brachytherapy, positron emission tomography (PET), single photon emission computed tomography (SPECT), target radionuclide therapy and peptide receptor radionuclide therapy (PRRT); radiopharmaceutical products, in particular actinium-containing and/or bismuth-containing radiopharmaceutical products in GMP [Good Manufacturing Practice] quality; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular actinium-225 and/or bismuth-213; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular actinium-225 and/or bismuth-213 for the treatment of tumour diseases; target radiopharmaceuticals containing a target molecule, in particular a peptide or an antibody, depending on the indication, and a medical radioactive isotope; radiopharmaceuticals containing actinium-225 and/or bismuth-213 and its complexes. (3) Medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, in particular for the production of actinium-225 and/or bismuth-213 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of actinium-225 and/or bismuth-213 in GMP quality; radionuclide generator for radiopharmaceutical purpose. (1) Scientific and technological services and research relating to the use of actinium-225 and/or bismuth-213 or other alpha emitters, in particular medical and pharmacological research services relating to the use of actinium-225 and/or bismuth-213 or other alpha emitters. (2) Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and radionuclide therapy, peptide receptor radionuclide therapy (PRRT), personal nuclear medicine and precision oncology; medical services for theranostics in the field of precision oncology.

Produits et services

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography (PET) or single photon emission tomography (SPECT), target radionuclide and peptide receptor radionuclide therapy (PRRT); theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumors; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET); radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; radiopharmaceuticals for use with high-sensitivity molecular imaging technologies such as PET (positron emission tomography) or SPECT (single photon emission tomography), for imaging organs and lesions and for early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumor diseases Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; control, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators for radiopharmaceutical purposes Conducting clinical trials in all stages and with various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) Medical services, in particular services in the field of radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapy, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy (PRRT), personal nuclear medicine and precision oncology

Produits et services

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, In particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; Theranostics in the field of precision oncology; Radiopharmaceutical products, Namely precursor compositions containing lutetium [precursors]; Solutions relating to radiolabelling; Radiopharmaceutical preparations for use in oncology, Namely radiopharmaceuticals containing radioisotopes, including lutetium-177, actinium-225, yttrium-90 for the treatment of, and radioisotopes including gallium-68 or fluor-18 for the diagnosis of tumours; Target radiopharmaceuticals containing a target molecule, including peptides or antibodies, independent of the indication and a medical radioactive isotope radiopharmaceutical containing gallium and complexes thereof, gallium-68 DOTATOC; 177 Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteritic or pancreatic origin [GEP-NET]; Radiopharmaceuticals for use in GEP-NET therapy, osteosarcomas, bone metastases, prostrate cancer, breast cancer, brain cancer, ovarian cancer; Radiopharmaceuticals containing radioisotopes with shirt half-lives, including gallium-68 or fluor-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technology including PET [positron emission tomography] or SPECT [single photon emission tomography], for the creation of images of organs and lesions and for early diagnosis of diseases; Radiopharmaceuticals containing medical radioisotopes with long half-lives, including lutetium-177, actinium-225 or yttrium-90 for the treatment of tumorous diseases. Medical instruments, apparatus and containers for the application of radiopharmaceutical preparations and radiodiagnostic preparations; Control, regulation and measuring apparatus being parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnostics with a radiotherapeutic or radiodiagnostic substance; Radionuclide generators for radiopharmaceutical purposes. Conducting of clinical studies in all stages and with a variety of indications, in particular in oncology; Conducting of clinical studies in phase III with the target radiopharmaceutical 177 Lu-edotreotide in patients with neuroendocrine tumours of gastroenteritic or pancreatic origin [GEP-NET]. Medical services, In particular services in the field of radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapy including intercavitary, interstitial and intravascular brachytherapies, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology.

Produits et services

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases. Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators for radiopharmaceutical purposes. Conducting clinical trials at all stages and in various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]. Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology.

Produits et services

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases. Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators for radiopharmaceutical purposes. Conducting clinical trials at all stages and in various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]. Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology.

Produits et services

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases. Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators for radiopharmaceutical purposes. Conducting clinical trials at all stages and in various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]. Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology.

Produits et services

(1) Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases. (2) Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; apparatus and containers with radiotherapeutic and radiodiagnostic substances for use in diagnosis and treatment in field of oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies; radionuclide generators for radiopharmaceutical purposes (1) Conducting clinical trials at all stages and in various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]. (2) Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology.

Produits et services

(1) Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEPNET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases (2) Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; apparatus and containers with radiotherapeutic and radiodiagnostic substances for use in diagnosis and treatment in field of oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies; radionuclide generators for radiopharmaceutical purposes (1) Conducting clinical trials at all stages and in various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET] (2) Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology

Produits et services

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope for diagnosis purposes; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes Conducting clinical trials for others at all stages and in various indications, particularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET] Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology

Produits et services

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope for diagnosis purposes; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes Conducting clinical trials for others at all stages and in various indications, particularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET] Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology

Produits et services

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope for diagnostic purposes; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes Conducting clinical trials for others at all stages and in various indications, particularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET] Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology

Produits et services

Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance, medical apparatus, namely, radionuclide generators for radiopharmaceutical purposes.

Produits et services

Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance, medical apparatus, namely, radionuclide generators for radiopharmaceutical purposes.

Produits et services

(1) Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEPNET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases (2) Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; apparatus and containers with radiotherapeutic and radiodiagnostic substances for use in diagnosis and treatment in field of oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies; radionuclide generators for radiopharmaceutical purposes (1) Conducting clinical trials at all stages and in various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]. (2) Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology.

Produits et services

Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance, medical apparatus, namely, radionuclide generators for radiopharmaceutical purposes.

Produits et services

(1) Radiopharmaceuticals, in particular gallium complexes and gallium DOTATOC.

Produits et services

Radiopharmaceuticals, in particular gallium complexes and gallium DOTATOC.

Produits et services

Radiopharmaceutical preparations, in particular gallium coordination complexes and gallium DOTATOC for treating and diagnosing tumors

Produits et services

Radiopharmaceuticals, in particular gallium complexes and gallium DOTATOC.

Produits et services

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, especially radiopharmaceutical preparations for endo radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography (PET), radionuclide generators for radiopharmaceutical purposes. Medical instruments, apparatus and containers for the application of radiopharmaceutical preparations and radiodiagnostic preparations; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, especially apparatus for therapy and diagnostics with a radiotherapeutic or radiodiagnostic substance. Medical services, especially services in the field of radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiologie and nuclear medicine as well as brachytherapy including intercavitary, interstitial and intravascular brachytherapies and PET-Scanning.

Produits et services

Radiopharmaceuticals, in particular gallium complexes and gallium DOTATOC.

Produits et services

Radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing lutetium for treating and diagnosing tumours; radiopharmaceuticals linked to somatostatin analogues.

Produits et services

(1) Radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing lutetium for treating and diagnosing tumours; radiopharmaceuticals consisting of radionuclides chemically coupled to somatostatin analogues

Produits et services

Radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing lutetium for treating and diagnosing tumours

Produits et services

Radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing lutetium for treating and diagnosing tumours; Radiopharmaceuticals linked to somatostatin analogues.

Produits et services

Radiopharmaceutical products, namely precursors containing lutetium; radioactive substances for medical purposes.

Produits et services

(1) Radiopharmaceutical products, namely precursors containing lutetium; solutions for radioactive labelling

Produits et services

Radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing lutetium for treating and diagnosing tumours.

Produits et services

Radiopharmaceutical preparations, namely, precursors containing lutetium for therapeutic or diagnostic purposes; Radioactive substances for medical purposes, namely, for radio-labelling pharmaceutical compounds for use in nuclear medicine

Produits et services

Radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing lutetium for treating and diagnosing tumours

Produits et services

(1) Radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing lutetium for treating and diagnosing tumours

Produits et services

Radiopharmaceutical products, Namely precursors containing lutetium; Solutions for radioactive labelling.

Produits et services

Radiopharmaceutical products, namely precursors containing lutetium; radioactive substances for medical purposes.

Produits et services

Radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing lutetium for treating and diagnosing tumours.

Produits et services

Radiopharmaceutical products, namely precursors containing lutetium; radioactive substances for medical purposes.

Produits et services

Radiopharmaceutical products, Namely precursors containing lutetium; Solutions for radioactive labelling.

Produits et services

(1) Radiopharmaceutical products, namely precursors containing lutetium; solutions for radioactive labelling

Produits et services

Radiopharmaceutical preparations, namely, precursors containing Lutetium for therapeutic or diagnostic purposes; Radioactive substances for medical purposes, namely, for radio-labelling pharmaceutical compounds for use in nuclear medicine

Produits et services

Radiopharmaceutical products, namely precursors containing lutetium; Solutions for radioactive labelling.

Produits et services

Pharmaceutical preparations and diagnostic preparations for medical purposes, radiotherapeutic preparations and radiodiagnostic preparations, radiopharmaceuticals for brachytherapy including a beta emitter, especially liquid rhenium. Medical instruments, apparatus and containers for the application of pharmaceutical preparations and diagnostic preparations, especially apparatus for therapy and diagnostic with a radiotherapeutic or radiodiagnostic substance compound; dosimeters, containers for substances, syringes, needles and catheters including balloon-catheters, brachytherapy equipment, all the aforementioned goods, where necessary, also equipped with radiation protection shieldings, as far as included in this class; scintillation counters, radiation detectors and radiation measuring assemblies, as far as included in this class. Medical services, especially services in the field of therapeutic and diagnostic cardiology, angiology, radiology, neuroradiologie and nuclear medicine as well as brachytherapy including intercavitary, interstitial and intravascular brachytherapies.

Produits et services

Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations and radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy, diagnostics and therapy of pain, diagnostics and therapy of inflammations, diagnostics and therapy of metabolic disorders, palliative therapy, ablative therapy, [ positrons emission stomatography (PTE), emission stomatography ] * positrons emission tomography (PET), emission tomography * with single photons (SPECT), x-ray diagnostics, gamma spectrometry, nuclear spin tomography, scintigraphy, dosimetry, radiopharmaceutic products, and medical products containing sources for radiation Medical devices for dosimetry purposes in the field of radiotherapy; radiation dosimeters for assessing therapeutic doses of radiation delivered to patients; medical devices and instruments for the application of pharmaceutical preparations and diagnostic preparations, namely, radioactive isotope generators and microfluidics instruments; medical apparatus and instruments for diagnostic radiopharmaceutical use; radioisotope therapy apparatus and instruments and parts thereof Medical services, especially services in the field of therapeutic and diagnostic cardiology, angiology, radiology, [ neuroradiologie ] * neuroradiology * and nuclear medicine as well as brachytherapy featuring intercavitary, interstitial and intravascular brachytherapies

Produits et services

(1) Radiotherapeutics for endovascular brachytherapy and for prophylaxis, treatment and therapy of stenosis and restenosis. (2) Injector for injecting a dosed application of radiotherapeutics and radiodiagnostics; radiodiagnostics for endovascular brachytherapy and for prophylaxis, treatment and therapy of stenosis and restenosis. (1) Medical services namely, endovascular brachytherapy and prophylaxis, treatment and therapy of stenosis and restenosis.

Produits et services

Pharmaceutical preparations and diagnostic preparations for medical purposes, especially radiotherapeutic preparations and radiodiagnostic preparations. Medical instruments, apparatus and containers for the application of pharmaceutical preparations and diagnostic preparations; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, especially apparatus for therapy and diagnostics with a radiotherapeutic or radiodiagnostic substance. Medical services.

Produits et services

Pharmaceutical preparations and diagnostic preparations for medical purposes, especially radiotherapeutic preparations and radiodiagnostic preparations. Medical instruments, apparatus and containers for the application of pharmaceutical preparations and diagnostic preparations; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, especially apparatus for therapy and diagnostics with a radiotherapeutic or radiodiagnostic substance. Medical services.

Produits et services

[ Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations and radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy, diagnostics and therapy of pain, diagnostics and therapy of inflammations, diagnostics and therapy of metabolic disorders, palliative therapy, ablative therapy, positrons emission stomatography (PTE), emission stomatography with single photons (SPECT), x-ray diagnostics, gamma spectrometry, nuclear spin tomography, scintigraphy, dosimetry, radiopharmaceutic products, and medical products containing sources for radiation ] Medical devices for dosimetry purposes in the field of radiotherapy; radiation dosimeters for assessing therapeutic doses of radiation delivered to patients; medical devices and instruments for the application of pharmaceutical preparations and diagnostic preparations, namely radioactive isotope generators and microfluidics instruments; medical apparatus and instruments for diagnostic radiopharmaceutical use; radioisotope therapy apparatus and instruments; and other control, regulation and measuring apparatuses, namely scintillation counters, flow meters, pH meters, chromatographic equipment, spectrometers, and biometric measuring instruments, comprising parts of medical instruments and devices, for therapy and diagnostics with a radiotherapeutic or radiodiagnostic substance [ Medical services ]

Produits et services

Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radio therapeutic preparations and radio diagnostic preparations used in the application of radioisotopes and radiation in medicine, namely, nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy, diagnostics and therapy of pain, diagnostics and therapy of inflammations, diagnostics and therapy of metabolic disorders, palliative therapy, ablative therapy, [ positrons emission stomatography (PTE), emission stomatography with single photons (SPECT), x-raydiagnostics, gamma spectrometry, nuclear spin tomography, scintigraphy, and dosimetry ] [ Medical devices for dosimetry purposes in the field of radiotherapy; radiation dosimeters for assessing therapeutic doses of radiation delivered to patients; ] medical devices and instruments for the application of pharmaceutical preparations and diagnostic preparations, namely, radioactive isotope generators [ and microfluidics instruments; medical apparatus and instruments for diagnostic radio pharmaceutical use; radioisotope therapy apparatus and instruments; and other control, regulation and measuring apparatuses, namely, scintillation counters, flow meters, pH meters, chromatographic equipment, spectrometers, and biometric measuring instruments, comprising parts of medical instruments ] and devices, for therapy and diagnostics with a radio therapeutic or radio diagnostic substance Medical services